Filip Garbicz

Physician searching for cures.

[Filip Garbicz @FilipGarbicz]

https://t.co/tYRRXMZWsP

[Filip Garbicz @FilipGarbicz]

https://t.co/qg1AJytdDc

[Filip Garbicz @FilipGarbicz]

https://t.co/OmB6YN9Bgh

[Filip Garbicz @FilipGarbicz]

https://t.co/h8RAULnRiF

[Crémieux @cremieuxrecueil]

Science is about to get absolutely nuked.

Unless we get extremely strict about providing and opening up code and data and documenting lab experiments rigorously, a torrent of credible-looking but fraudulent papers is upon us.

[Papa Heme @Papa_Heme]

Before you call it MDS, check a copper level — vacuolized precursors on the marrow are your clue, and the cytopenias are completely reversible.

Who gets copper deficiency?
Bariatric surgery patients
People who take too much zinc supplements

[Filip Garbicz @FilipGarbicz]

yup...

[unusual_whales @unusual_whales]

AI chatbots misdiagnose in over 80% of early medical cases, per FT.

[Filip Garbicz @FilipGarbicz]

@BoWang87 There is a lot of labeling errors in this image.
How about we go back to having some human touch in those scientific illustrations? So that they are... correct?

This ain't microvilli... Looks like my vitamin D capsule

[Nicholas Hornstein @GIMedOnc]

Drug development is supposed to be linear.

Build the drug → use the drug → resistance shows up → then figure out what to do next.

Aaaand not what Revolution Medicines is doing. 🧬

At #AACR26 they disclosed RM-055, which honestly is a unique concept.

Before daraxonrasib is even fully in the world, they’re building around resistance.

How it works:

• Most mutant RAS proteins are relatively resistant to GAP-mediated hydrolysis
• That helps keep RAS in the active state
• They’ve found a way to enhance that hydrolysis with RM-055

RM-055 can:
• restore hydrolysis in mutant RAS
• flatten daraxonrasib-resistant models
• generate activity even in RAS-amplified settings 👀

That’s a very smart way to think about this space.

Not just “here’s our inhibitor.”

More like: we already know resistance to our drug is coming, so let’s start building now.

That’s how we cure cancer, not more me-toos (if I hear about another new PD1 program I’m going to cry).

@OncoAlert @TheGutOncLab @Onco_Nexus

[Filip Garbicz @FilipGarbicz]

https://t.co/EJHRYQsMd5

[Yakup Ergün @dr_yakupergun]

One of the most notable studies from #AACR26:

Daraxonrasib + gem/nab-paclitaxel shows a strong early signal in 1L mPDAC.

ORR 58%
DCR 90%
6-month PFS 84%!!

Things are finally moving in pancreatic cancer👇

https://t.co/ijyGOW6hmE

[Jonathan Reiner @JReinerMD]

Long term follow up of a phase 1
trial of an mRNA tumor vaccine shows that 7/8 patients with pancreatic cancer, who mounted an immune response to the vaccine, are still alive 6 years later. This is breathtaking data and shows the promise of mRNA vaccines. https://t.co/J1kDmMRZQY

[Filip Garbicz @FilipGarbicz]

@DanaFarber @broadinstitute LINK:
https://t.co/jteOcJIixl

[Filip Garbicz @FilipGarbicz]

Our new paper in Nature Communications is out (@NatureComms):
How does a single mutation in a ribosomal protein drive blood cancer?

[Filip Garbicz @FilipGarbicz]

Incredibly proud of our team at @DanaFarber, the @broadinstitute , and collaborators across the globe.

#CancerResearch #Leukemia #CLL #Ribosomes #Genomics #Oncology #leuSM #lymSM

[Nicholas Hornstein @GIMedOnc]

RevMed absolutely stole the show at AACR with their Pan-RAS and G12D inhibitors.

First line panc, second line NSCLC, even in early trials this is extremely compelling data.

2L NSCLC anti G12D (early data):
PFS: 11 months
ORR: 52%
G3 AEs: 13%

(Now compare that to 10 months with Osimertinib in 2L NSCLC)…

This can’t be FDA approved soon enough.

@OncoAlert @TheGutOncLab